AstraZeneca
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.About AZN
AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology.
AZN Key Statistics
Stock Snapshot
With a market cap of 250.41B, AstraZeneca(AZN) trades at $161.46. The stock has a price-to-earnings ratio of 24.15 and currently yields dividends of 1.68%.
On 2026-09-08, AstraZeneca(AZN) stock moved within a range of $160.61 to $164.21. With shares now at $161.46, the stock is trading +0.5% above its intraday low and -1.7% below the session's peak.
Trading activity shows a volume of 1.41M, compared to an average daily volume of 2.88M.
Over the past 52 weeks, AstraZeneca(AZN) stock has traded between a high of $212.71 and a low of $145.79.
Over the past 52 weeks, AstraZeneca(AZN) stock has traded between a high of $212.71 and a low of $145.79.
AZN News
AstraZeneca said a Tagrisso plus Orpathys global Phase 3 trial was the first to show significant progression-free and overall survival benefits in its setting....
The latest announcement is out from AstraZeneca ( (GB:AZN) ). On 8 September 2026, AstraZeneca reported positive interim Phase III results from the Amgen-spons...
The drug, tozorakimab, achieved reductions in moderate and severe COPD exacerbations by around 30% compared with the standard therapy in two late-stage studies....
Analyst ratings
100%
of 10 ratingsMore AZN News
Amgen (AMGN) announced results from the Phase 3 DeLLphi-305 study, which met its primary endpoint at a pre-specified interim analysis, demonstrating a statistic...
Positive high-level results from a planned interim analysis of the DeLLphi-305 Phase III trial showed IMFINZI plus Amgen’s (AMGN) tarlatamab demonstrated a stat...
...
AstraZeneca AZN announced that the FDA has approved Etcamah (camizestrant) in combination with a medicine belonging to the class of cyclin-dependent kinase (CDK...
AstraZeneca ( (GB:AZN) ) has shared an update. AstraZeneca has secured U.S. accelerated approval for its oral selective estrogen receptor degrader Etcamah (cam...
The U.S. Food and Drug Administration expanded treatment options for adult patients with advanced breast cancer, reflecting the FDA’s commitment to advancing me...
AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. AstraZeneca has launched a new Phase I study, formally titled “A Phase I, Single-...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.